2923687-56-1
2923687-56-1
Chemical Structure
Itanistomig
Synonym(s): LB-101
- CAS No.: 2923687-56-1
- Formula:N/A
- Molecular Weight:(243.635 kDa)
SMILES: [Itanistomig]
Biological Activity: Itanistomig (LB-101) is a tetravalent bispecific antibody targeting PD-L1 and CD47. Itanistomig blocks PD-L1 and achieves tumor enrichment through binding to PD-L1, and also exerts conditional CD47 blocking activity via cleavage of the hinge linker in the PD-L1-positive tumor microenvironment. Itanistomig induces antibody-dependent cellular phagocytosis in human CD14+ cells and drives tumor regression. Itanistomig can be used in research related to solid tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Itanistomig | 95.84% | Itanistomig (LB-101) is a tetravalent bispecific antibody targeting PD-L1 and CD47. Itanistomig blocks PD-L1 and achieves tumor enrichment through binding to PD-L1, and also exerts conditional CD47 blocking activity via cleavage of the hinge linker in the PD-L1-positive tumor microenvironment. Itanistomig induces antibody-dependent cellular phagocytosis in human CD14+ cells and drives tumor regression. Itanistomig can be used in research related to solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
-
[1]. Finlay J, et al. LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody (mAb), combines tumor microenvironment (TME) targeted delivery (PD-L1) and a single biological high potency effector (CD47).
- [2]. Brinkmann U, et al. The making of multispecific immunoglobulins - a clinical perspective. MAbs. 2026;18(1):2613548. [Content Brief]
